TrialNature communications2025

An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial.

Meagan E Deming et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.